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Introduction Paraoxonase 1 (PON1) is a multifunctional enzyme associated with high-density lipoprotein 
particles (HDL). It is a cellular antioxidant that hydrolyses oxidized macromolecules, especially low-density 
lipoproteins (ox-LDL). Because increased oxidative stress is believed to play a crucial role in the initiation 
and propagation of atherosclerosis, coding (Q192R and L55M) and promoter (C(-107)T) region polymor-
phisms of pon1 gene, that are responsible for catalytic efficiency, activity and the level of the enzyme, 
have been of great interest as a potential markers of susceptibility for atherogenesis.
Objective The aim of the study was to assess possible association between these pon1 gene variants 
and clinical manifestations of the atherosclerosis and oxidative stress.
Methods A total of 60 angiographically documented patients with manifested atherosclerotic disease 
and 100 control individuals were analyzed. Genomic DNA was isolated from the peripheral blood cells 
and genotyping was performed using polymerase chain reaction followed by the restriction fragment 
length polymorphism (PCR-RFLP) analysis.
Results No significant difference in allele and genotype frequencies of all three examined polymorphisms 
was found between the atherosclerotic patients and healthy controls. The obtained results could not 
support an association of pon1 gene variants with the oxidative stress and atherogenesis.
Conclusion These polymorphisms cannot be considered risk factors of atherosclerosis in Serbian popula-
tion. A larger study is required in order to establish possible contribution of pon1 variants to atheroscle-
rosis-related cardiovascular diseases.
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INTRODUCTION
According to World Health Organization 
(WHO) [1] data for 2010, 95% of mortality in 
Serbia is caused by chronic non-contagious dis-
eases, wherefrom 58% is caused by cardiovas-
cular diseases (CVD). Although patients with 
CVD commonly have at least one identifiable 
risk factor, many ischemic events occur in the 
absence of any of them [2]. Atherogenesis, one 
of the main risk factors of CVD, is initiated by 
oxidation of the low-density lipoprotein (LDL) 
and by impairment of the oxidative stress-anti-
oxidant balance. For this reason, there has been 
a profound interest in discovering the addition-
al markers of oxidative stress, including gene 
variants, which may have a role in predicting 
the risk of disease.
Paraoxonase 1 (PON1) is a calcium depend-
ent high density lipoprotein (HDL)-associated 
esterase (with paraoxonase, arylesterase and 
lactonase activities). The enzyme was named 
“paraoxonase” according to its ability to hydro-
lyse paraoxon, the toxic metabolite of the orga-
nophosphate insecticide parathion and later it 
was shown that it exhibited a broad spectrum 
of activities and had diverse substrates. When 
Mackness and colleagues connected PON1 
with cardiovascular diseases in 1991 and dem-
onstrated that PON1 could prevent the ac-
cumulation of oxidized lipids in low-density 
lipoprotein (LDL) [3], this cellular antioxidant 
became one of the most studied molecules in 
cardiovascular medicine. Despite intensive re-
search, the exact physiological role of PON1 
and mechanism of action have been still un-
explained.
PON1 is the product of pon1 gene, a mem-
ber of paraoxonase gene family (along with 
pon2 and pon3) located on the long arm of the 
chromosome 7 in humans (7q21.3-22.1) [4]. 
PON1 mRNA expression is limited to the liver 
but it associates with HDL in the circulation. 
In the coding region, two of the most studied 
polymorphisms are: glutamine to arginine sub-
stitution at codon 192 (Q192R) and leucine to 
methionine substitution at position 55 (L55M) 
[5, 6]. At least five polymorphisms have been 
detected in the pon1 gene promoter region 
[C(-107/-108)T, G(-126)C, G(-162)A, G(-832)
A and G(-909)C], but only C(-107T) seems to 
be significant for enzyme function [7, 8].
Polymorphisms R192Q and M55L in the 
coding and C (-107)T in the promoter region 
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have the greatest impact on PON1 activity and concen-
tration. R192Q polymorphism has been, so far, the most 
investigated. It determines isoforms of the enzyme which 
differ highly in the rate of hydrolysis of certain substrates 
[9], and it has been shown that position 192 is involved in 
HDL binding, stability, lipolactonase activity, and macro-
phage cholesterol efflux [10]. L55 isoform is more stable 
and more resistant to proteolysis than the M55 form, con-
sequently it is related to blood enzyme levels. The C(-107)
T polymorphism has the strongest effect on PON1 expres-
sion with C allele being associated with two-fold higher 
level of enzyme as compared with T allele [7, 8].
OBJECTIVE
All three polymorphisms have been associated with a 
number of pathological conditions and the present study 
investigated the role of these pon1 gene variants against the 
risk of clinical manifestations of atherosclerosis.
METHODS
A total of 60 patients with angiographically documented 
atherosclerosis (37 males and 23 females, age 30-80 years) 
treated at Dedinje Cardiovascular Institute and Zvezdara 
University Medical Center, Belgrade, Serbia from 2010-
2011 were included in the study. The control group was 
composed of 100 healthy individuals, age and sex matched 
with cases. Participants were not related and originated 
from different parts of Serbia. The study was approved by 
the Ethics Board of Zvezdara University Medical Center.
Genomic DNA was extracted from peripheral blood 
cells by DNeasy Blood & Tissue Kit (Qiagen), and isolated 
DNA was stored at +4°C until further analysis.
Pon1 L55M, Q192R and C(-107)T genotyping was per-
formed using the polymerase chain reaction-restriction 
fragment length polymorphism analysis (PCR-RFLP) as 
previously described [6, 11]. PCR mixture (total volume 
20 µl) contained 2X PCR Master Mix (2X-concentrated 
solution containing Taq DNA polymerase, reaction buff-
er, MgCl2, and dNTP, Fermentas Life Sciences), 0.5 µM of 
each primer (Metabion) and 0.2 µg of genomic DNA. The 
PCR reactions were carried out for each polymorphism 
separately. Digestion products were separated on 3 % aga-
rose gel, stained with ethidium bromide (0.5 μg/ml) and 
visualised under UV light for genotype determination.
Statistical analysis was carried out using SPSS software 
(version 17). Allele and genotype frequencies in cases and 
controls were compared using the chi-square test and the 
risk was assessed by means of the logistic regression analy-
sis. A p value <0.05 was considered significant.
RESULTS
Two polymorphisms in the coding (Q192R and L55M) and 
one in the promoter region (C-107T) of pon1 gene were 
analyzed. The allele and genotype frequency distribution 
for the three analyzed polymorphisms in both patients and 
controls was given in Table 1.
There was no significant difference in allele and geno-
type frequencies for Q192R between the cases and con-
trols. Frequencies of Q and R alleles and QQ, QR and RR 
genotypes were equal or almost equal in the two groups 
(Table 1).
The results of logistic regression analysis suggested that 
neither alleles nor genotypes of this polymorphism carried 
any risk of disease (Table 2).
No significant difference in the L55M polymorphism 
was found after comparing allele and genotype frequen-
cies between the groups (p>0.05) (Table 1). Likewise, no 
association with disease risk could be observed for any of 
the alleles or genotypes. 
Though C allele was more frequent in the patient group 
(57%) compared to the controls (43%) for the C(-107)T 
SNP, the difference, however, failed to reach statistical sig-
nificance (Table 1). Similarly, none of the values obtained 
by the logistic regression analysis showed statistical sig-
nificance indicating that this polymorphism could not be 
considered susceptibility factor (Table 2).
DISCUSSION
This is the first study dealing with the association between 
three polymorphisms in the pon1 gene, namely Q192R, 
L55M and C(-107)T, and the development of atheroscle-
rosis in Serbia.
It has been shown that paraoxonase 1 (PON1) has its 
role in atherogenesis: it protects LDL, HDL and macro-
phages against oxidative stress, as indicated by decreased 
macrophage intake of the oxidized LDL particles, inhibi-
tion of cholesterol synthesis and stimulation of HDL medi-
ated cholesterol efflux within macrophages. These func-
tions are related to lactonase activity of this enzyme [12, 
13]. PON1 hydrolyses lipid peroxides and prevents their 
accumulation in LDL and HDL particles in vitro and in 
vivo [14]. Moreover, PON1 preserves the integrity of HDL 
and is responsible for its anti-oxidative and anti-inflamma-
tory effects. Individuals with higher HDL and lower PON1 
serum concentrations are more prone to atherosclerosis 
and coronary heart disease (CHD) than individuals with 
lower HDL and higher PON1 [15].
In our study, there are no statistically significant differ-
ences in the distribution of alleles and genotypes for the 
Q192R polymorphism between the cases and the controls, 
which is compatible with the results of some other studies 
[16, 17]. This means that none of the alleles or genotypes 
represent a risk factor of development of atherosclerosis 
in Serbian population. Apart from the fact that it is lo-
cated within the active site of the enzyme and affects the 
substrate specificity of the enzyme [5, 6, 9], the position 
192 in the protein is also included in the binding to HDL 
particles [10]. Even though the R isoform of the enzyme 
has been associated with the increased risk of the oxidative 
stress and the incidence of the clinical manifestations of 
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atherosclerosis, especially CHD, it appears that Q isozyme 
represents a less stable form with lower lipolactonase ac-
tivity and, therefore, with lower antiatherogenic capacity 
[9, 10].
L55M polymorphism, which is located in the N-termi-
nal part of PON1, plays a role in binding of the enzyme 
to HDL, and thus may alter the ability of PON1 to form a 
complex with HDL [10, 18]. The allele L and genotype LL 
are associated with higher level of enzyme and with higher 
antioxidative protection as well [10, 11]. In addition, the 
polymorphism L55M affects the level of PON1, since the 
M isoform (MM genotype) is more susceptible to proteoly-
sis than other isoforms [18]. In our study, the frequency of 
L allele was higher within the control group compared to 
the subjects, as expected, while the frequency of M alleles 
was higher in the patients group although without statisti-
cal significance. Djurić et al. [19] analyzed the frequency of 
L55M polymorphism in Parkinson’s disease patients from 
Serbia, another disease related to oxidative stress, and their 
results support the assumption that MM genotype is a risk 
factor of disease progression. It is evident that the allele 
M is more frequent among patients compared to the con-
trols in both studies from our region, though the results 
of our study are not statistically significant. The study of 
Taşkiran and coworkers showed association between the 
L55M polymorphisms and coronary artery disease (CAD) 
but not between Q192R polymorphism, in Turkish popula-
tion [20].
The third polymorphism analyzed in the present study 
is the SNP C(-107)T in the promoter region of pon1 which 
also strongly affects gene expression as well as PON1 se-
rum levels. Recorded frequency of the C allele is higher 
within the case group compared to the controls, while the 
allele T is less frequent in comparison with the controls. 
Table 1. The allele and genotype frequencies of pon1 gene polymorphisms Q192R, L55M and C(-107)T in patient and control groups






Q (Gln)a 88 (73.0) 145 (72.5)
R (Arg) 32 (27.0) 55 (27.5) 0.03 0.86
Genotype frequency (%)
QQa 33 (55.0) 53 (53.0)
QR 22 (36.7) 39 (39.0) 0.08 0.78
RR 5 (8.3) 8 (8.0) 0.00 1.00
L55M
Allele frequency (%)
L (Leu)a 76 (63.0) 136 (68.0)
M (Met) 44 (37.0) 64 (32.0) 0.73 0.39
Genotype frequency (%)
LLa 20 (33.3) 45 (45.0)
LM 36 (60.0) 46 (46.0) 2.65 0.10
MM 4 (6.7) 9 (9.0) 0.00 1.00
C(-107)T
Allele frequency (%)
Ca 68 (57.0) 94 (47.0)
T 52 (43) 106 (53.0) 2.80 0.09
Genotype frequency (%)
CCa 20 (33.3) 21 (21.0)
CT 28 (47.7) 52 (52.0) 2.15 0.14
TT 12 (20.0) 27 (27.0) 2.70 0.10
a – reference allele and genotype; χ2 – Chi-square test; p – probability 
Table 2. The logistic regression analysis of pon1 gene polymorphisms Q192R, L55M i C(-107)T distribution in patient and control groups
pon1 Polymorphism Patients  (n=60)
Controls
(n=100) OR 95%CI p
Q192R
Allele frequency (%)
Q (Gln) 88 (73.0) 145 (72.5) 1.00 reference
R (Arg) 32 (27.0) 55 (27.5) 0.96 0.57–1.6 0.86
Genotype frequency (%)
QQ 33 (55.0) 53 (53.0) 1.00 reference
QR 22 (36.7) 39 (39.0) 0.91 0.46–1.79 0.78
RR 5 (8.3) 8 (8.0) 1.00 0.3–3.33 0.99
QQ+QR vs RR 55/5 92/8 1.04 0.3–3.4 0.94
L55M
Allele frequency (%)
L (Leu) 76 (63.0) 136 (68.0) 1.00 reference
M (Met) 44 (37.0) 64 (32.0) 1.23 0.76–1.98 0.39
Genotype frequency (%)
LL 20 (33.3) 45 (45.0) 1.00 reference
LM 36 (60.0) 46 (46.0) 1.76 0.89–3.49 0.10
MM 4 (6.7) 9 (9.0) 1.00 0.27–3.63 1.00
LL+LM vs MM 56/4 91/9 0.72 0.21–2.45 0.60
C(-107)T
Allele frequency (%)
C 68 (57.0) 94 (47.0) 1.00 reference
T 52 (43.0) 106 (53.0) 0.67 0.43–1.07 0.09
Genotype frequency (%)
CC 20 (33.3) 21 (21.0) 1.00 reference
CT 28 (47.7) 52 (52.0) 0.56 0.26–1.21 0.14
TT 12 (20.0) 27 (27.0) 0.46 0.18–1.10 0.10
CC+CT vs TT 48/12 73/27 0.68 0.31–1.46 0.31
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High frequency of T allele (53%) in the control group co-
incides with the frequency of this allele in Spanish popula-
tion [21], which has the highest T allele frequency (54%) 
among European nations so far examined [21-24]. No 
association between “low expressor” genotype TT and 
atherosclerosis has been found in the present study. James 
and collaborators have analyzed C(-107)T in patients who 
suffer from type 2 diabetes with or without ischemic heart 
disease and patients who suffer from coronary artery dis-
ease, and determined that TT represents a risk factor of 
these diseases [18, 25].
A meta-analysis dealing with L55M, Q192R and C-
107T polymorphisms in relation to CHD demonstrated 
only a weak positive overall association between Q192R 
polymorphism and CHD, while the remaining L55M and 
C(-107)T polymorphisms had no relevance [27]. Con-
siderable variations from one population to another in 
allele and genotype frequencies have been found, espe-
cially in the promoter region C(-107)T and the coding 
region Q192R. Accordingly, the results of studies dealing 
with the association of pon1 polymorphisms and cardio-
vascular disease risk in various populations proved to 
be heterogeneous and showed that each polymorphism 
separately affected only weakly complex disease such as 
atherosclerosis.
CONCLUSION
Our study evaluated PON1 polymorphisms distribution 
within Serbian population of the atherosclerotic patients 
and healthy controls. No significant differences in the ex-
amined pon1 gene variants were found between the con-
trols and patients, indicating that these polymorphisms are 
not risk factors of atherosclerosis in Serbian population. 
A larger cohort is required in order to establish accurately 
the possible contribution of the examined polymorphisms 
to atherosclerosis-related cardiovascular diseases.
ACKNOWLEDGMENT
This study is a part of the PhD thesis of Ivana Grubiša and 
has been financed by the grant 175075 of the Ministry of 
Education, Science and Technological Development of the 
Republic of Serbia.
REFERENCES
1. World Health Organization (WHO) [Internet] 2011. 
Noncommunicable diseases country profiles 2011. Available from: 
http://www.who.int/nmh/publications/ncd_profiles2011/en/.
2. Futterman LG, Lemberg L. Fifty percent of patients with coronary 
artery disease do not have any of the conventional risk factors. Am J 
Crit Care. 1998; 7(3):240-4.
3. Mackness M, Arrol S, Durrington PN. Paraoxonase prevents 
accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 
1991; 286(1-2):152–4. Erratum in: FEBS Lett 1991; 292(1-2):307.
4. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human 
serum paraoxonase/arylesterase gene (PON1) is one member of a 
multigene family. Genomics. 1996; 33(3):498-507.
5. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the 
polymorphic forms of human serum paraoxonase/ arylesterase: 
glutamine or arginine at position 191, for the respective A or B 
allozymes. Am J Hum Genet. 1993; 53:598-608.
6. Humbert R, Adler DA, Disteche CM, Omiecinski CJ, Furlong CE. The 
molecular basis of the human serum paraoxonase polymorphisms. 
Nat Genet. 1993; 3(1):73-6.
7. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, 
Furlong CE. Effects of 5’ regulatory-region polymorphisms on 
paraoxonase-gene (PON1) expression. Am J Hum Genet. 2001; 
68(6):1428-36.
8. Leviev I, James RW. Promoter polymorphisms of human 
paraoxonase PON1 gene and serum paraoxonase activities and 
concentrations. Arterioscler Thromb Vasc Biol. 2000;  
20(2):516-21.
9. Costa LG, Cole TB, Furlong CE. Paraoxonase (PON1): from toxicology 
to cardiovascular medicine. Acta Biomed. 2005; 76 Suppl 2:50-7.
10. Gaidukov L, Rosenblat M, Aviram M, Tawfik DS. The 192R/Q 
polymorphs of serum paraoxonase PON1 differ in HDL binding, 
lipolactonase stimulation, and cholesterol efflux. J Lipid Res. 2006; 
47(11):2492-502.
11. Flekač M, Škrha J, Zídková K, Lacinová Z, Hilgertová J. Paraoxonase 
1 gene polymorphisms and enzyme activities in diabetes mellitus. 
Physiol Res. 2008; 57(5):717-26.
12. Aviram M, Kaplan M, Rosenblat M, Fuhrman B. Dietary antioxidants 
and paraoxonases against LDL oxidation and atherosclerosis 
development. Handb Exp Pharmacol. 2005; (170):263-300.
13. Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more 
potent antioxidant and stimulant of macrophage cholesterol efflux, 
when present in HDL than in lipoprotein-deficient serum: relevance 
to diabetes. Atherosclerosis. 2006; 187(1):74-81.
14. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. 
Human serum paraoxonase (PON) Q and R selectively decrease lipid 
peroxides in human coronary and carotid atherosclerotic lesions: 
PON1 esterase and peroxidase-like activities. Circulation. 2000; 
101(21):2510-7.
15. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez 
CJ, Castellani LW, et al. Mildly oxidized LDL induces an increased 
apolipoprotein J/paraoxonase ratio. J Clin Invest. 1997; 99(8):2005-
19. Erratum in J Clin Invest. 1997; 99(12):3043.
16. Bayrak A, Bayrak T, Tokgözoğlu SL, Volkan-Salanci B, Deniz A, Yavuz B, 
et al. Serum PON1-1activity but not Q192R polymorphism is related 
to the extent of atherosclerosis. J Atheroscler Thromb. 2001; 18:1-9.
17. Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahvanainen E, 
Jauhiainen M, et al. The Gln-Arg 191 polymorphism of the human 
paraoxonase gene (HUMPONA) is not associated with the risk of 
coronary artery disease in Fins. J Clin Invest. 1996; 98(4):883-5.
18. Leviev I, Deakin S, James RW. Decreased stability of the M54 isoform 
of paraoxonase as a contributory factor to variations in human 
serum paraoxonase concentrations. J Lipid Res. 2001; 42(4):528-35.
19. Djurić G, Svetel M, Nikolaević SI, Dragadević N, Gavrilović J, Kostić 
VS. Polymorphisms in the genes of cytochrome oxidase P450 2D6 
(CYP2D6), paraoxonase 1 (PON1) and apolipoprotein E (APOE) as risk 
factors for Parkinson’s disease. Vojnosanit Pregl. 2007; 64(1):25-30.
20. Taşkiran P, Cam SF, Sekuri C, Tüzün N, Alioğlu E, Altintaş N, et al. The 
relationship between paraoxonase gene Leu-Met (55) and Gln-Arg 
(192) polymorphisms and coronary artery disease. Turk Kardiyol 
Dern Ars. 2009; 37(7):473-8.
21. Parra S, Alonso-Villaverde C, Coll B, Ferré N, Marsillach J, Aragonès 
G, et al. Serum paraoxonase-1 activity and concentration 
are influenced by human immunodeficiency virus infection. 
Atherosclerosis. 2007; 194(1):175-81.
22. Sardo MA, Campo S, Bonaiuto M, Bonaiuto A, Saitta C, Trimarchi 
G, et al. Antioxidant effect of atorvastatin is independent of 
PON1 gene T(-107)C, Q192R and L55M polymorphisms in 
hypercholesterolaemic patients. Curr Med Res Opin. 2005; 
21(5):777-84.
23. Clarimon J, Eerola J, Hellström O, Tienari PJ, Singleton A. 
Paraoxonase 1 (PON1) gene polymorphisms and Parkinson’s disease 
in a Finnish population. Neurosci Lett. 2004; 367(2):168-70.
24. Grdić M, Barišić K, Rumora L, Salamunić I, Tadijanović M, Žanić-
Grubišić T, et al. Genetic frequencies of paraoxonase 1 gene 
polymorphisms in Croatian population. Croat Chem Acta. 2008; 
81:105-11.
    
633Srp Arh Celok Lek. 2013 Sep-Oct;141(9-10):629-633
www.srp-arh.rs
25. James RW, Leviev I, Ruiz J, Passa P, Froguel P, Garin MC. Promoter 
polymorphism T(-107)C of the paraoxonase PON1 gene is a risk 
173 factor for coronary heart disease in type 2 diabetic patients. 
Diabetes. 2000; 49(8):1390-3.
26. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four 
paraoxonase gene polymorphisms i 11212 cases of coronary heart 
disease and 12786 controls: meta-analysis of 43 studies. Lancet. 
2004; 363(9410):689-95.
КРАТАК САДРЖАЈ
Увод Па ра ок со на за 1 (PON1) је мул ти функ ци о нал ни ен зим 
ко ји је ве зан за ли по про те и не ви со ке гу сти не (HDL). То је 
ће лиј ски ан ти ок си данс ко ји хи дро ли зу је ок си до ва не ма-
кро мо ле ку ле, на ро чи то ок си до ва не ли по про те и не ни ске 
гу сти не (ox-LDL). Сма тра се да по ви ше ни ок си да тив ни стрес 
игра кључ ну уло гу у ини ци ја ци ји и про па га ци ји ате ро скле-
ро зе, па су по ли мор фи зми у ко ди ра ју ћем (Q192R и L55M) и 
про мо тор ском (C(-107)T) ре ги о ну ге на pon1, ко ји су од го вор-
ни за ка та ли тич ку ефи ка сност, ак тив ност и ни во ен зи ма, од 
ве ли ког ин те ре са као по тен ци јал ни мар ке ри осе тљи во сти 
на ате ро ге не зу.
Циљ ра да Циљ ове сту ди је је био да се испита мо гу ћа по-
везаност ва ри јан ти ге на pon1 и кли нич ких ма ни фе ста ци ја 
ате ро скле ро зе и ок си да тив ног стре са.
Ме то де ра да Ана ли зи ра но је 60 бо ле сни ка с ан ги о граф-
ски до ку мен то ва ним ма ни фе ста ци ја ма ате ро скле ро зе и 100 
здра вих ис пи та ни ка. Ге ном ска ДНК је изо ло ва на из ће ли ја 
пе ри фер не кр ви, а ге но ти пи за ци ја је ура ђе на при ме ном ре-
ак ци је лан ча не по ли ме ра зе, по сле ко је је ура ђе на ана ли за 
ду жи не ре стрик ци о них фраг ме на та (тзв. PCR-RFLP ана ли за).
Ре зул та ти Уче ста ло сти але ла и ге но ти по ва три ис пи ти ва-
на по ли мор фи зма ни су по ка за ле зна чај не раз ли ке из ме ђу 
ис пи та ни ка обо ле лих од ате ро скле ро зе и здра вих осо ба. 
До би је ни ре зул та ти не ука зу ју на по ве за ност ана ли зи ра них 
ва ри јан ти ге на pon1 и ок си да тив ног стре са и ате ро ге не зе.
За кљу чак Ови по ли мор фи зми се не мо гу сма тра ти фак то-
ри ма ри зи ка за раз вој ате ро скле ро зе у срп ској по пу ла ци ји. 
По треб на је сту ди ја са ве ћим бро јем ис пи та ни ка, ка ко би се 
утвр дио мо гу ћи до при нос ва ри јан ти ге на pon1 на на ста нак 
кар ди о ва ску лар них обо ље ња у чи јој осно ви је ате ро скле-
ро за.
Кључ не ре чи: па ра ок со на за 1; ге не тич ки по ли мор фи зми; 
ок си да тив ни стрес; ате ро ге не за
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